Department of Emergency Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Emergency Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
J Med Virol. 2022 Jul;94(7):3240-3250. doi: 10.1002/jmv.27737. Epub 2022 Apr 19.
To observe the predictive effect of fasting blood glucose (FBG) level on the prognosis, clinical sequelae, and pulmonary absorption in hospitalized coronavirus disease 2019 (COVID-19) patients with and without a history of diabetes, respectively, and to evaluate the correlation between the dynamic changes of FBG and poor prognosis. In this bidirectional cohort study, we enrolled 2545 hospitalized COVID-19 patients (439 diabetics and 2106 without a diabetic history) and followed up for 1 year. The patients were divided according to the level of admission FBG. The dynamic changes of FBG were compared between the survival and the death cases. The prediction effect of FBG on 1-year mortality and sequelae was analyzed. The 1-year all cause mortality rate and in-hospital mortality rate of COVID-19 patients were J-curve correlated with FBG (p < 0.001 for both in the nondiabetic history group, p = 0.004 and p = 0.01 in the diabetic history group). FBG ≥ 7.0 mmol/L had a higher risk of developing sequelae (p = 0.025) and have slower recovery of abnormal lung scans (p < 0.001) in patients who denied a history of diabetes. Multivariable Cox regression analysis showed that FBG ≥ 7.0 mmol/L was an independent risk factor for the mortality of COVID-19 regardless of the presence or deny a history of diabetes (hazard atio [HR] = 10.63, 95% confidence interval [CI]: 7.15-15.83, p < 0.001; HR = 3.9, 95% CI: 1.56-9.77, p = 0.004, respectively). Our study shows that FBG ≥ 7.0 mmol/L can be a predictive factor of 1-year all-cause mortality in COVID-19 patients, independent of diabetes history. FBG ≥ 7.0 mmol/L has an advantage in predicting the severity, clinical sequelae, and pulmonary absorption in COVID-19 patients without a history of diabetes. Early detection, timely treatment, and strict control of blood glucose when finding hyperglycemia in COVID-19 patients (with or without diabetes) are critical for their prognosis.
观察空腹血糖(FBG)水平对合并或不合并糖尿病的住院 2019 冠状病毒病(COVID-19)患者预后、临床后遗症和肺部吸收的预测作用,并评估 FBG 动态变化与不良预后的相关性。在这项双向队列研究中,我们纳入了 2545 例住院 COVID-19 患者(439 例糖尿病患者和 2106 例无糖尿病病史患者),并随访 1 年。根据入院时 FBG 水平将患者进行分组。比较存活与死亡病例之间 FBG 的动态变化。分析 FBG 对 1 年死亡率和后遗症的预测作用。COVID-19 患者的 1 年全因死亡率和院内死亡率与 FBG 呈 J 型相关(无糖尿病病史组 p < 0.001,糖尿病病史组 p = 0.004 和 p = 0.01)。FBG ≥ 7.0 mmol/L 使无糖尿病病史患者发生后遗症的风险更高(p = 0.025),且异常肺部扫描恢复更慢(p < 0.001)。多变量 Cox 回归分析显示,FBG ≥ 7.0 mmol/L 是 COVID-19 患者死亡的独立危险因素,无论是否合并糖尿病史(合并糖尿病史 HR = 10.63,95%CI:7.15-15.83,p < 0.001;无糖尿病史 HR = 3.9,95%CI:1.56-9.77,p = 0.004)。本研究表明,FBG ≥ 7.0 mmol/L 可预测 COVID-19 患者 1 年全因死亡率,与糖尿病史无关。FBG ≥ 7.0 mmol/L 对预测无糖尿病病史 COVID-19 患者的严重程度、临床后遗症和肺部吸收具有优势。早期发现、及时治疗和严格控制 COVID-19 患者(合并或不合并糖尿病)的高血糖对改善其预后至关重要。